Key facts
as of Sep 2026- It has raised $20.6M; the latest was Early Stage VC ($20.6M) in Mar 2025.
- Notable investors include HSG (Hong Kong), Shanghai Guofang Private Equity Fund Management Company, Wuxi AstraZeneca CICC Venture Capital Partnership, Bayland Capital, Med-Fine Capital — 8 tracked in total.
- 2 institutional filers report fund marks on Danatlas Pharmaceutical across 15 filings.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Danatlas Pharmaceutical
- ·The full record, as it builds
Recorded secondary trades
No secondary trades in Danatlas Pharmaceutical shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
2 filers · latest May 20262 SEC-registered funds reported 15 fair-value marks on Danatlas Pharmaceutical between Apr 2025 and May 2026. Filer-level marks and implied $/share are available to Pro members.
Funding rounds
No funding rounds for Danatlas Pharmaceutical are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Danatlas Pharmaceutical
Developer of drugs designed for oncology treatment. The company is committed to developing drugs that precisely target the "world first (FIC)" targets in the era of tumor precision 2.0 to meet the clinical needs of patients and promote medical innovation, providing patients with transformative treatment.
- Sector
- Healthcare
- HQ
- Beijing, China
- Founded
- 2021
- Website
- danatlas.com/
- Ownership
- Privately Held (backing)